Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -377.11% is 66% below its 5-year average of -227.81%, around the middle of its 5-year range (-1121.53%–66.56%).
52.56% above its 12-month average of -794.88%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -734.95%.
OPERATING MARGIN
-377.11%
OPERATING MARGIN AVG TTM
-794.88%
OPERATING MARGIN AVG 3Y
-395.98%
OPERATING MARGIN AVG 5Y
-227.81%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+52.56%
CURRENT VS 3Y AVG
+4.77%
CURRENT VS 5Y AVG
-65.54%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Immatics N.V.
Market Cap
$1.01B
Operating Margin
-377.11%
TTM Avg
-794.88%
3Y Avg
-395.98%
5Y Avg
-227.81%
Market Cap
$998.69M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-59.79%
Market Cap
$996.65M
Operating Margin
-33.86%
TTM Avg
-38.38%
3Y Avg
-66.13%
5Y Avg
-173.51%
Market Cap
$1.02B
Operating Margin
-8.99%
TTM Avg
-4.92%
3Y Avg
-23.48%
5Y Avg
-24.49%
Market Cap
$992.14M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.02B
Operating Margin
-1576.67%
TTM Avg
-1255.13%
3Y Avg
-1048.04%
5Y Avg
-849.59%
Market Cap
$982.46M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.03B
Operating Margin
1.38%
TTM Avg
4.21%
3Y Avg
3.61%
5Y Avg
3.61%
Market Cap
$981.66M
Operating Margin
-130.20%
TTM Avg
-311.82%
3Y Avg
-583.08%
5Y Avg
-487.88%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immatics N.V. (IMTX) | $1.01B | -377.11% | -794.88% | -395.98% | -227.81% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | 0.00% | 0.00% | 0.00% | -59.79% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | -33.86% | -38.38% | -66.13% | -173.51% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | -8.99% | -4.92% | -23.48% | -24.49% |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | -1576.67% | -1255.13% | -1048.04% | -849.59% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | 1.38% | 4.21% | 3.61% | 3.61% |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | -130.20% | -311.82% | -583.08% | -487.88% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
Gross Margin
100.0%
Operating Margin
-377.1%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -734.95% |
| 2026-03-31 | -867.89% |
| 2025-12-31 | -196.76% |
| 2025-09-30 | -1053.27% |
| 2025-06-30 | -1121.53% |
| 2025-03-31 | -190.37% |
| 2024-12-31 | 1.61% |
| 2024-09-30 | 1.02% |
| 2024-06-30 | -141.64% |
| 2024-03-31 | -44.50% |
| 2023-12-31 | -174.07% |
| 2023-09-30 | -561.37% |
| 2023-06-30 | -64.04% |
| 2023-03-31 | -269.80% |
| 2022-12-31 | 0.12% |
| 2022-09-30 | -145.58% |
| 2022-06-30 | -96.76% |
| 2022-03-31 | 66.56% |
| 2021-12-31 | -102.12% |
| 2021-09-30 | -356.99% |
| 2021-06-30 | -450.88% |
| 2021-03-31 | -322.00% |
| 2020-12-31 | -212.05% |
| 2020-09-30 | -238.81% |
| 2020-06-30 | -284.21% |
| 2020-03-31 | -160.24% |
| 2019-12-31 | -280.16% |
| 2019-09-30 | -153.40% |
| 2019-06-30 | -117.74% |
| 2019-03-31 | -183.01% |
| 2018-12-31 | -912.71% |
| 2018-09-30 | -912.71% |
| 2018-06-30 | -912.71% |
| 2018-03-31 | -912.71% |
